Company
Tallac Therapeutics
Harnessing the power of NEXT GENERATION ADCs to fight cancer
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Tallac Therapeutics™ is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer using antibody drug conjugates (ADCs).
Funding snapshot
- Total raised
- $61.6MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $61.6M2020-06-23
Funding rounds
- Round, 2020
- $61.6M2020-06-23, SEC form D sold, 12 investors
Loading relationship preview